Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SACICUP
2025-523055-55-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacituzumab govitecan in cancer of unknown primary (CUP) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2025-523055-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523055-55-00.